Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

te into our Phase 3 development plan. We believe such endpoints are the only critical and relevant primary endpoints for Phase 3 trials in patients with CRPC and for ultimately achieving marketing approval."

Results from our Phase 2 clinical development program are summarized below:

    -   First Line Prostate Cancer Potential Survival Advantage - longer
        survival duration, estimated at 10.6 months, in a randomized Phase 2
        clinical trial of OGX-011 in combination with docetaxel and
        prednisone ("the OGX-011 arm") when compared to docetaxel alone ("the
        control arm") for first-line treatment of metastatic CRPC. The median
        survival was 27.5 months for the patients in the OGX-011 arm and 16.9
        months for those in the control arm. Results currently indicate that
        patients in the OGX-011 arm have a death rate of approximately 40%
        lower than patients in the control arm. Additional survival updates
        are needed before a mature median survival for the OGX-011 arm can be
        reported; however, based on the current results, OncoGenex has
        calculated that the final median survival for patients in the OGX-011
        arm cannot be lower than 22.7 months, representing at least a 5.8
        month median survival benefit. For comparison, docetaxel was approved
        for treatment of metastatic CRPC by the FDA based on a survival
        advantage of 2.4 months over mitoxantrone.

    -   Second Line Prostate Cancer Potential Survival Advantage - longer
        than expected survival durations for patients receiving OGX-011 in
        combination with either mitoxantrone or docetaxel retreatment as
        second-line chemotherapy as compared to reported survival durations
        in two published studies of CRPC patients receiving second-line
        chemotherapy. As of January 14, 2009, the median survival duration
        for the randomized 20 patien
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:10/1/2014)... Sept. 30, 2014 This report ... in US$ Million by the following Product ... Enzymes. Specific end-use segments also analyzed are ... The report provides separate comprehensive analytics ... Middle East, and Latin America. Annual estimates ...
(Date:9/30/2014)... is available in German . ... several quantum dots in a semiconductor layer. Quantum dots are ... atomic processes. If a short laser pulse is fired at ... quantum dot experiences a change in the electromagnetic field around ... emission of light by the dot. As soon as the ...
(Date:9/30/2014)... news release is available in German . ... the Technische Universitt Mnchen (TUM) have demonstrated a new ... experiments show that future computer chips could be based ... As the main enabling technology of the semiconductor industry ... limits, the TUM researchers and collaborators at the University ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Ultrafast remote switching of light emission 2A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3
... LAFAYETTE, Ind. - The National Nuclear Security Administration has ... center at Purdue University,s Discovery Park to develop advanced ... Friday (March 7). , The center will focus on ... one of five new Centers of Excellence chosen by ...
... LLY ) today announced the termination of development ... partnership with Alkermes,Inc. The program has been in phase ... and type 2 diabetes. The company noted that this,decision ... Insulin trials,relating to the safety of the product, but ...
... CHICAGO, March 7 Advanced Life Sciences,Holdings, Inc. ... has received notice,from the Nasdaq Listing Qualifications Department ... the bid price for the Company,s,common stock has ... for,continued inclusion under Marketplace Rule 4310(c)(4) (the "Rule"). ...
Cached Biology Technology:Purdue leads center to simulate behavior of micro-electromechanical systems 2Purdue leads center to simulate behavior of micro-electromechanical systems 3Purdue leads center to simulate behavior of micro-electromechanical systems 4Lilly Announces Termination of AIR Insulin Program 2Lilly Announces Termination of AIR Insulin Program 3Lilly Announces Termination of AIR Insulin Program 4Advanced Life Sciences Receives Nasdaq Notification 2Advanced Life Sciences Receives Nasdaq Notification 3
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... species in the Amazon will survive even grim scenarios ... extinction rates of up to 50 percent, predict Smithsonian ... the journal Proceedings of the National Academy of ... be as they weather the next several decades of ...
... Medical Center and at the National Institute of Environmental ... chromosomes can recombine to change genomes and spawn new ... of repeated sequences in the genomes of most higher ... many repeats," said Lucas Argueso, Ph.D., a research scholar ...
... When you make a new material on a nano scale ... team lead by a Biotechnology and Biological Sciences research Council ... major challenge faced by nanotechnology scientists. With new research ... from the University of Liverpool, The School of Pharmacy (University ...
Cached Biology News:Extinction most likely for rare trees in the Amazon rainforest 2Duke-NIEHS team shows how DNA repairs may reshape the genome 2Scientists overcome nanotech hurdle 2Scientists overcome nanotech hurdle 3
... surface is produced by a patented microwave ... giving more consistent, even cell attachment, increased ... attachment and growth uunder difficult conditions, including ... may provide a more ecominic alternative to ...
Automated Cell Culture Flask...
... 100-240 V, uses xMAP technology for simultaneous ... and peptides in one microplate well. The ... 100 color-coded bead sets, each of which ... (enzyme substrates, receptors, antigens, or antibodies) specific ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: